JP2013505201A - 広域反応性中和抗ｈｉｖ抗体を誘導するための配合物 - Google Patents

広域反応性中和抗ｈｉｖ抗体を誘導するための配合物 Download PDF

Info

Publication number
JP2013505201A
JP2013505201A JP2012503432A JP2012503432A JP2013505201A JP 2013505201 A JP2013505201 A JP 2013505201A JP 2012503432 A JP2012503432 A JP 2012503432A JP 2012503432 A JP2012503432 A JP 2012503432A JP 2013505201 A JP2013505201 A JP 2013505201A
Authority
JP
Japan
Prior art keywords
ligand
mper
tnd
hiv
epitope
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012503432A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013505201A5 (enExample
Inventor
アラム，エス・ムニール
ヘインズ，バートン・エフ
セカラン，モーゼス・ディー
トマラス，ジョージア
シェン，シャオイーン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Duke University
Original Assignee
Duke University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Duke University filed Critical Duke University
Publication of JP2013505201A publication Critical patent/JP2013505201A/ja
Publication of JP2013505201A5 publication Critical patent/JP2013505201A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Dispersion Chemistry (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2012503432A 2009-04-03 2010-04-05 広域反応性中和抗ｈｉｖ抗体を誘導するための配合物 Pending JP2013505201A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16662509P 2009-04-03 2009-04-03
US61/166,625 2009-04-03
PCT/US2010/001017 WO2010114628A2 (en) 2009-04-03 2010-04-05 Formulation for inducing broadly reactive neutralizing anti-hiv antibodies

Publications (2)

Publication Number Publication Date
JP2013505201A true JP2013505201A (ja) 2013-02-14
JP2013505201A5 JP2013505201A5 (enExample) 2013-11-21

Family

ID=42828908

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012503432A Pending JP2013505201A (ja) 2009-04-03 2010-04-05 広域反応性中和抗ｈｉｖ抗体を誘導するための配合物

Country Status (6)

Country Link
US (1) US9402917B2 (enExample)
EP (1) EP2413951A4 (enExample)
JP (1) JP2013505201A (enExample)
AU (1) AU2010232915A1 (enExample)
CA (1) CA2757240A1 (enExample)
WO (1) WO2010114628A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1868651A4 (en) 2005-04-12 2010-10-06 Univ Duke METHOD FOR INDUCTION OF NEUTRALIZING ANTIBODIES TO THE HIV VIRUS
EP2139516A4 (en) * 2007-04-13 2011-06-29 Univ Duke METHOD FOR INDUCING NEUTRALIZING ANTIBODY AGAINST HIV
US20120070488A1 (en) * 2007-09-28 2012-03-22 Duke University Method of inducing neutralizing antibodies to human immunodeficiency virus
US20140322262A1 (en) * 2007-09-28 2014-10-30 Duke University Method of inducing neutralizing antibodies to human immunodeficiency virus
AU2010232915A1 (en) 2009-04-03 2011-10-20 Duke University Formulation for inducing broadly reactive neutralizing anti-HIV antibodies
JP2013520498A (ja) * 2010-02-25 2013-06-06 デューク ユニバーシティー 防御的抗ｈｉｖ−１抗体の産生を誘導する方法
EP2668201A2 (en) * 2011-01-28 2013-12-04 Sanofi Pasteur SA Immunological compositions comprising hiv gp41 polypeptide derivatives
WO2014020205A2 (es) * 2012-07-31 2014-02-06 Universidad De Granada Inmunógenos anti-vih mejorados
EP3872097A1 (en) 2012-10-19 2021-09-01 The Council Of The Queensland Institute Of Medical Research Improved human herpesvirus immunotherapy
WO2015048635A1 (en) 2013-09-27 2015-04-02 Duke University Mper-liposome conjugates and uses thereof
WO2024097957A1 (en) * 2022-11-03 2024-05-10 Duke University Novel antibodies for hiv and methods of making and using the same

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006512391A (ja) * 2002-12-30 2006-04-13 スリーエム イノベイティブ プロパティズ カンパニー 組み合わせ免疫賦活薬
WO2008127651A1 (en) * 2007-04-13 2008-10-23 Duke University Method of inducing neutralizing antibodies to human immunodeficiency virus

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ263373A (en) 1993-03-11 1997-05-26 Univ Southern California Monoclonal antibodies and use against immunoinfective cluster viruses
DE69433013T2 (de) 1993-05-27 2004-06-03 Entremed, Inc. Zubereitungen und verfahren für die behandlung von krebs und hyperproliferierenden krankheiten
FI963638A7 (fi) 1994-03-14 1996-11-13 Univ Southern California Menetelmiä HIV-1-injektion diagnosoimiseksi ja hoitamiseksi
US6156337A (en) 1994-07-08 2000-12-05 Opperbas Holding B.V. Method for high loading of vesicles with biopolymeric substances
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
EP1250933A1 (en) * 2001-04-17 2002-10-23 Istituto Superiore di Sanità Vaccines including as an adjuvant high dose type I IFN
EP1613643A4 (en) 2003-03-27 2009-10-28 Sudhir Paul LUPUS ANTIBODIES FOR PASSIVE IMMUNOTHERAPY AGAINST HIV / AIDS
EP1868651A4 (en) 2005-04-12 2010-10-06 Univ Duke METHOD FOR INDUCTION OF NEUTRALIZING ANTIBODIES TO THE HIV VIRUS
US20080057075A1 (en) 2005-04-12 2008-03-06 Haynes Barton F Method of inducing neutralizing antibodies to human immunodeficiency virus
UY31101A1 (es) 2007-05-24 2009-01-05 Glaxosmithkline Biologicals Sa Composición antigénica liofilizada
US20120070488A1 (en) 2007-09-28 2012-03-22 Duke University Method of inducing neutralizing antibodies to human immunodeficiency virus
US20140322262A1 (en) 2007-09-28 2014-10-30 Duke University Method of inducing neutralizing antibodies to human immunodeficiency virus
WO2009111304A2 (en) 2008-02-29 2009-09-11 President And Fellows Of Harvard College A fusion-intermediate state of hiv-1 gp41 targeted by broadly neutralizing antibodies
SMT202000101T1 (it) 2008-10-10 2020-03-13 Childrens Medical Center Vaccino con trimero di env di hiv-1 stabilizzato biochimicamente
WO2010045613A1 (en) 2008-10-16 2010-04-22 New York Blood Center Immunoenhancer-linked oligomeric hiv vaccines
AU2010232915A1 (en) 2009-04-03 2011-10-20 Duke University Formulation for inducing broadly reactive neutralizing anti-HIV antibodies
CA2757306A1 (en) * 2009-04-03 2010-10-07 Duke University Formulation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006512391A (ja) * 2002-12-30 2006-04-13 スリーエム イノベイティブ プロパティズ カンパニー 組み合わせ免疫賦活薬
WO2008127651A1 (en) * 2007-04-13 2008-10-23 Duke University Method of inducing neutralizing antibodies to human immunodeficiency virus

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
JPN6013008064; Ｊ．ＩＭＭＵＮＯＬ． ＶＯＬ．１７８，　ＮＯ．３, 20070201, Ｐ．１５６４-１５７２ *
JPN6014024763; Ｊ　Ｉｍｍｕｎｏｌ，　ｖｏｌ．１７８，　ｐ．４４２４-４４３５　（２００７） *
JPN6014024765; ＰＮＡＳ，　ｖｏｌ．１０７，　ｐ．５９７２-５９７７　（２０１０） *
JPN6014024767; Ｊ　Ｖｉｒｏｌ，　ｖｏｌ．８２，　ｐ．１１５-１２５　（２００８） *
JPN6014024768; Ｊ　Ｖｉｒｏｌ，　ｖｏｌ．８２，　ｐ．６８６９-６８７９　（２００８） *

Also Published As

Publication number Publication date
WO2010114628A9 (en) 2010-11-25
US20120128758A1 (en) 2012-05-24
AU2010232915A1 (en) 2011-10-20
EP2413951A2 (en) 2012-02-08
US9402917B2 (en) 2016-08-02
EP2413951A4 (en) 2015-05-20
WO2010114628A3 (en) 2011-03-10
CA2757240A1 (en) 2010-10-07
WO2010114628A2 (en) 2010-10-07

Similar Documents

Publication Publication Date Title
US9402917B2 (en) Methods for the induction of broadly anti-HIV-1 neutralizing antibody responses employing liposome-MPER peptide compositions
Haynes et al. Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates
Dennison et al. Induction of antibodies in rhesus macaques that recognize a fusion-intermediate conformation of HIV-1 gp41
US10588960B2 (en) Liposome-peptide conjugate and method of using same to induce production of anti-HIV antibodies
Liu et al. The development of HIV vaccines targeting gp41 membrane-proximal external region (MPER): challenges and prospects
US20150147387A1 (en) Method of inducing antibodies to human immunodeficiency virus involving the administration of mper peptide-liposome conjugates
US20080057075A1 (en) Method of inducing neutralizing antibodies to human immunodeficiency virus
US10076567B2 (en) MPER-liposome conjugates and uses thereof
JP2015508279A (ja) Ｈｉｖｇｐ−１２０改変体の迅速選択法
Koornneef et al. CoPoP liposomes displaying stabilized clade C HIV-1 Env elicit tier 2 multiclade neutralization in rabbits
US20120070488A1 (en) Method of inducing neutralizing antibodies to human immunodeficiency virus
US20110159037A1 (en) Methods of treating and protecting against human immunodeficiency virus
US20140322262A1 (en) Method of inducing neutralizing antibodies to human immunodeficiency virus
US20250073328A1 (en) Compositions and methods for treating or preventing hiv infection
US20110293697A1 (en) HIV-1 Immunogenic Compositions
CN101588813A (zh) 诱导人类免疫缺陷病毒的中和抗体的方法
Watson Lipopeptide immunogens targeting the membrane proximal region of HIV-1 gp41
Melnychuk Optimization of an HIV-1 clade C DNA vaccine
WO2017007646A1 (en) Hiv-1 clade c envelope glycoproteins
AU2014202366A1 (en) Method of Inducing Neutralizing Antibodies to Human Immunodeficiency Virus
JP2015532591A (ja) Ｈｉｖｇｐ１２０変異体のための迅速な免疫原選択改良法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130405

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130405

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131003

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140616

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140916

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140924

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20141016

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20141023

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150128